Study Objective: Insomnia impacts the course of major depressive disorder (MDD), hinders response to treatment, and increases risk for depressive relapse.
This study is an initial evaluation of adding cognitive behavioral therapy for insomnia (CBTI) to the antidepressant medication escitalopram (EsCIT) [brand name LexaproR in the U.S., a type of selective serotonin reuptake inhibitor] in individuals with both disorders.
Design and setting: A randomized, controlled, pilot study in a single academic medical center.
Participants: 30 individuals (61% female, mean age 35±18) with MDD and insomnia.
Interventions: EsCIT and 7 individual therapy sessions of CBTI or CTRL (quasi-desensitization).
Measurements and results: Depression was assessed with the HRSD17 and the depression portion of the SCID, administered by raters masked to treatment assignment, at baseline and after 2, 4, 6, 8, and 12 weeks of treatment.
The primary outcome was remission of MDD at study exit, which required both an HRSD17 score = 7 and absence of the 2 core symptoms of MDD. Sleep was assessed with the insomnia severity index (ISI), daily sleep diaries, and actigraphy.
EsCIT + CBTI resulted in a higher rate of remission of depression (61.5%) than EsCIT + CTRL (33.3%). EsCIT + CBTI was also associated with a greater remission from insomnia (50.0%) than EsCIT + CTRL (7.7%) and larger improvement in all diary and actigraphy measures of sleep, except for total sleep time.
Conclusion: This pilot study provides evidence that augmenting an antidepressant medication with a brief, symptom focused, cognitive behavioral therapy for insomnia is promising for individuals with MDD and comorbid insomnia in terms of alleviating both depression and insomnia.
Source: Sleep. April 2008. 31(4); pp 489-495, by Manber R, Edinger JD, Gress JL, San Pedro-Salcedo MG, Kuo TF, Kalista T. Stanford University, Stanford, California; VA Medical Center and Duke University Medical Center, Durham, North Carolina, USA.